Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis

Biochemical and Biophysical Research Communications

Volumn 391, Issue 1, 2010, Pages 1080-1086

  Min, Soo Hong ^a   Wang, Yuanfan ^a   Gonsiorek, Waldemar ^a   Anilkumar, Gopinadhan ^a   Kozlowski, Joseph ^a   Lundell, Daniel ^a   Fine, Jay S ^a   Grant, Ethan P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Arthritis; CCR2; CXCR2; Migration; Pharmacodynamics; Pharmacology

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCL1; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CYTOKINE; LIGAND; MK 0812; SCH 563705; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CARTILAGE DEGENERATION; CELL COUNT; CELL MIGRATION; CELL POPULATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; INFLAMMATION; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RECEPTOR BLOCKING; TREATMENT OUTCOME;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL MOVEMENT; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED BALB C; NEUTROPHILS; RECEPTORS, CCR2; RECEPTORS, INTERLEUKIN-8B; SYNOVIAL FLUID;

EID: 72949103055     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.12.025     Document Type: Article

References (21)

1. Gerard C., and Rollins B.J. Chemokines and disease. Nat. Immunol. 2 (2001) 108-115
2. Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat. Rev. Drug Discov. 8 (2009) 23-33
3. Kitsis E., and Weissmann G. The role of the neutrophil in rheumatoid arthritis. Clin. Orthop. Relat. Res. (1991) 63-72
4. Iwamoto T., Okamoto H., Toyama Y., and Momohara S. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J. 275 (2008) 4448-4455
5. Koch A.E. Chemokines and their receptors in rheumatoid arthritis: future targets?. Arthritis Rheum. 52 (2005) 710-721
6. Nandakumar K.S., Svensson L., and Holmdahl R. Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am. J. Pathol. 163 (2003) 1827-1837
7. Tanaka D., Kagari T., Doi H., and Shimozato T. Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology 119 (2006) 195-202
8. Barsante M.M., Cunha T.M., Allegretti M., Cattani F., Policani F., Bizzarri C., Tafuri W.L., Poole S., Cunha F.Q., Bertini R., and Teixeira M.M. Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats. Br. J. Pharmacol. 153 (2008) 992-1002
9. Coelho F.M., Pinho V., Amaral F.A., Sachs D., Costa V.V., Rodrigues D.H., Vieira A.T., Silva T.A., Souza D.G., Bertini R., Teixeira A.L., and Teixeira M.M. The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature. Arthritis Rheum. 58 (2008) 2329-2337
10. Grespan R., Fukada S.Y., Lemos H.P., Vieira S.M., Napimoga M.H., Teixeira M.M., Fraser A.R., Liew F.Y., McInnes I.B., and Cunha F.Q. CXCR2-specific chemokines mediate leukotriene B4-dependent recruitment of neutrophils to inflamed joints in mice with antigen-induced arthritis. Arthritis Rheum. 58 (2008) 2030-2040
11. Chao J., Taveras A.G., Chao J., Aki C., Dwyer M., Yu Y., Purakkattle B., Rindgen D., Jakway J., Hipkin W., Fosetta J., Fan X., Lundell D., Fine J., Minnicozzi M., Phillips J., and Merritt J.R. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists. Bioorg. Med. Chem. Lett. 17 (2007) 3778-3783
12. Voulgari P.V. Emerging drugs for rheumatoid arthritis. Expert Opin. Emerg. Drugs 13 (2008) 175-196
13. Haringman J.J., Gerlag D.M., Smeets T.J., Baeten D., van den Bosch F., Bresnihan B., Breedveld F.C., Dinant H.J., Legay F., Gram H., Loetscher P., Schmouder R., Woodworth T., and Tak P.P. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 54 (2006) 2387-2392
14. Vergunst C.E., Gerlag D.M., Lopatinskaya L., Klareskog L., Smith M.D., van den Bosch F., Dinant H.J., Lee Y., Wyant T., Jacobson E.W., Baeten D., and Tak P.P. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 58 (2008) 1931-1939
15. Quinones M.P., Ahuja S.K., Jimenez F., Schaefer J., Garavito E., Rao A., Chenaux G., Reddick R.L., Kuziel W.A., and Ahuja S.S. Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J. Clin. Invest. 113 (2004) 856-866
16. Bruhl H., Cihak J., Plachy J., Kunz-Schughart L., Niedermeier M., Denzel A., Rodriguez Gomez M., Talke Y., Luckow B., Stangassinger M., and Mack M. Targeting of Gr-1+, CCR2+ monocytes in collagen-induced arthritis. Arthritis Rheum. 56 (2007) 2975-2985
17. Cardona A.E., Sasse M.E., Liu L., Cardona S.M., Mizutani M., Savarin C., Hu T., and Ransohoff R.M. Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood 112 (2008) 256-263
18. Kagari T., Doi H., and Shimozato T. The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J. Immunol. 169 (2002) 1459-1466
19. Kalinowska A., and Losy J. Investigational C-C chemokine receptor 2 antagonists for the treatment of autoimmune diseases. Expert Opin. Investig. Drugs 17 (2008) 1267-1279
20. Proudfoot A.E. Is CCR2 the right chemokine receptor to target in rheumatoid arthritis?. Arthritis Rheum. 58 (2008) 1889-1891
21. Tsou C.L., Peters W., Si Y., Slaymaker S., Aslanian A.M., Weisberg S.P., Mack M., and Charo I.F. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. 117 (2007) 902-909